PubMed

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.

Cardiovasc Diabetol. 2009 Feb 26;8:12.PMID: 19245711 [PubMed - indexed for MEDLINE]Related articlesFree article

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.

Pharmacotherapy. 2009 Nov;29(11):1280-8.PMID: 19873688 [PubMed - in process]Related articles

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

Diabet Med. 2009 Mar;26(3):268-78.PMID: 19317822 [PubMed - indexed for MEDLINE]Related articles

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.

Diabetologia. 2009 Oct;52(10):2046-55. Epub 2009 Aug 14.PMID: 19688338 [PubMed - indexed for MEDLINE]Related articlesFree article

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M.

Postgrad Med. 2009 May;121(3):5-15.PMID: 19491535 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.

Herman WH, Dirani RG, Horblyuk R, O'Neill MC, Kravitz B, Heise MA, Bakst A, Freed MI; RESULT Study Group.

Am J Manag Care. 2005 Apr;11(4):273-8.PMID: 15839187 [PubMed - indexed for MEDLINE]Related articlesFree article

Liraglutide: a review of its use in type 2 diabetes mellitus.

Croom KF, McCormack PL.

Drugs. 2009 Oct 1;69(14):1985-2004. doi: 10.2165/11201060-000000000-00000. Review.PMID: 19747013 [PubMed - indexed for MEDLINE]Related articles

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

Lancet. 2009 Feb 7;373(9662):473-81. Epub 2008 Sep 24.PMID: 18819705 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.PMID: 16800160 [PubMed - indexed for MEDLINE]Related articles

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. Epub 2009 Jun 8.PMID: 19515413 [PubMed - indexed for MEDLINE]Related articles

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group.

Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):417-23.PMID: 17039422 [PubMed - indexed for MEDLINE]Related articles

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Campbell RK.

Ann Pharmacother. 2009 Sep;43(9):1433-44. Epub 2009 Jul 28. Review.PMID: 19638470 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team.

Lancet. 2009 Jun 20;373(9681):2125-35. Epub 2009 Jun 6.PMID: 19501900 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.PMID: 17636824 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.

Pfützner A, Wilhelm B, Forst T.

Vasc Health Risk Manag. 2007;3(2):211-20. Review.PMID: 17580731 [PubMed - indexed for MEDLINE]Related articlesFree article

[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus]

Fehér J, Lengyel G.

Orv Hetil. 2007 Dec 9;148(49):2331-5. Hungarian. PMID: 18048112 [PubMed - indexed for MEDLINE]Related articles

Potential of liraglutide in the treatment of patients with type 2 diabetes.

Deacon CF.

Vasc Health Risk Manag. 2009;5(1):199-211. Epub 2009 Apr 8. Review.PMID: 19436648 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55.PMID: 18435673 [PubMed - indexed for MEDLINE]Related articles

Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.

Drab SR.

Pharmacotherapy. 2009 Dec;29(12 Pt 2):43S-54S.PMID: 19947816 [PubMed - in process]Related articles

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.

Diabetes Care. 2009 Jan;32(1):84-90. Epub 2008 Oct 17.PMID: 18931095 [PubMed - in process]Related articlesFree article